Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Assenagon Asset Management cut its Amneal Pharmaceuticals stake by 20.3% in the second quarter, selling 621,812 shares but retaining 2.45 million shares valued at approximately $42.3 million.
• Amneal shares opened at $18.14, near their 52-week high of $19.26, and have risen above their 50-day and 200-day moving averages. The company reported quarterly revenue of $722.5 million and EPS of $0.27.
• Analyst sentiment remains favorable, with seven Buy ratings and one Hold rating, producing a consensus “Moderate Buy” rating and an average price target of $17.67.

Assenagon Asset Management S.A. lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 20.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,445,549 shares of the company's stock after selling 621,812 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.77% of Amneal Pharmaceuticals worth $42,332,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth about $26,000. Federated Hermes Inc. raised its holdings in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company's stock valued at $29,000 after acquiring an additional 2,168 shares during the period. Transamerica Financial Advisors LLC lifted its position in Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company's stock worth $37,000 after acquiring an additional 2,460 shares during the last quarter. Comerica Bank lifted its position in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company's stock worth $30,000 after acquiring an additional 1,957 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $52,000. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $18.14 on Friday. The business has a fifty day moving average price of $16.79 and a two-hundred day moving average price of $14.44. The stock has a market capitalization of $5.79 billion, a PE ratio of 37.02 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $8.21 and a fifty-two week high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on AMRX shares. The Goldman Sachs Group reiterated a "buy" rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Weiss Ratings upgraded Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, July 29th. Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 20th. UBS Group lifted their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the firm's stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director directly owned 93,660 shares of the company's stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.30% of the stock is owned by insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source